Today, we’re thrilled to announce our $200M Series C funding round at a $1B valuation, led by @RoboStrategy and existing investors including @generalcatalyst. Standard Bots is now America’s largest manufacturer of AI-native industrial robots. Our customers include Sunoco, Lockheed Martin, NASA, and the US Army along with hundreds of other manufacturers across the country. We’re proud to say that we’re on track to deploy 10% of all U.S. industrial robots by next year. We are expanding our Glen Cove, New York facility to 70,000 square feet to scale our vertically integrated production process. We currently design almost all our own parts, including our own actuators, and we assemble every final product in-house. By 2027, we’ll manufacture everything — from metal in to robots out — right here in America. We believe AI-native robots are the essential power tool of the 21st century — the tool that will grow American manufacturing and help every American worker to be a force at work. You just show your robot how it’s done, and it learns through demonstration. No coding, no consultants, just unbox and deploy faster than anything else on the market. Right now it’s possible for the United States to revitalize our manufacturing base if we become the worldwide leader in this transformative technology. We must build American robots, and put them to work in American factories. It’s a national imperative, and it’s our central mission. This fundraise gets us one step closer to the goal. The future of American manufacturing is bright! Join Standard Bots, and show your robot how it’s done — we’re just getting started.

"What if the model companies do this?" is the new "What if Google does this?" I.e. the meaningless question investors ask that shows either that they're stupid or that they dislike you and are looking for ways to find fault.

🤯 JUST IN: INCREDIBLE PHASE 3 DATA ON RETATRUTIDE PRESENTED AT ADA At ADA this weekend, Eli Lilly ($LLY ) presented new Phase 3 data from TRIUMPH-1 and TRANSCEND-T2D-1. BLUF: 28% (70 pounds) weight loss. Unreal. In TRIUMPH-1, participants receiving 12 mg of retatrutide lost an average of 70.3 pounds (28.3%) over 80 weeks. Nearly half achieved at least 30% weight loss, and 65.3% were no longer classified as obese (BMI <30) by the end of the study. Among participants who started with BMI ≥35 and continued treatment to 104 weeks, average weight loss reached 85 pounds (30.3%), with no evidence that weight loss had fully plateaued. What stood out more was the breadth of effect across obesity-related conditions: Knee osteoarthritis pain improved by 73.1% Obstructive sleep apnea severity improved by 60.6% Triglycerides fell by as much as 41.0% Non-HDL cholesterol declined by 24.2% Systolic blood pressure dropped by 12.3 mmHg Waist circumference decreased by 9.5 inches Meanwhile, in TRANSCEND-T2D-1, retatrutide produced A1C reductions of up to 2.0% from a baseline of 7.9%. 90% of patients achieved A1C <7% 85% achieved A1C ≤6.5% 46% reached A1C <5.7%, which is below the threshold used to define prediabetes Patients lost 36.6 pounds (16.8%) at 40 weeks, and weight loss was still ongoing at study end. Obesity medicine is increasingly becoming outcomes medicine. Historically, we have evaluated obesity drugs primarily on percent weight loss... but payers ultimately care about sleep apnea, osteoarthritis, diabetes, cardiovascular risk, and healthcare costs. The significance of TRIUMPH-1 and TRANSCEND-T2D-1 is that Lilly is beginning to show a coherent story across those endpoints, not just body weight. I expect this to expand coverage dramatically. Eli Lilly is the Nvidia of healthcare.

Allen Control Systems has raised a $200M Series B led by Smash Capital, with participation from @craft_ventures, @rallyvc, and @InspiredCap. Low-cost drones are reshaping modern conflict, and the demand for proven counter-drone defense is accelerating. This funding enables us to scale Bullfrog, the most trusted kinetic solution built for the U.S. military and allied partners worldwide. We're hiring across manufacturing, engineering, and operations to scale the next generation of counter-drone defense.

My current lifemaxxing stack: - 4:30am wake up - Read classic books - 3 hours creative work before 8am - Lift/run 6x/week - Eat single ingredient foods - Present time with fam/friends - 20-min evening sauna - Wild Roman skincare routine - 8:30pm bedtime Wouldn't change a thing.

Scoop: Smash leads $200M deal for defense-tech Allen Control Systems axios.com/2026/06/05/smash-a…

So we have legal MSO txns ticking up given ABS clarity. Simultaneously, Harvey/Legora etc coming down to mid market from AmLaw 100. I wonder how a 50 lawyer firm in Ohio chooses between those 2 paths (liquidity event for 20% of the biz versus adopt legal AI tooling themselves)

A software company can issue equity to attract a world-class CTO. A law firm usually can't. That's one reason MSOs are becoming more popular, and the future of legal may depend as much on technologists and operators as it does on lawyers. x.com/BLaw/status/2061387330…

Kirkland & Ellis, the world's highest-grossing law firm, is setting aside $500M to build its own AI platform rather than rely on tools available to its rivals (Financial Times) (Visit Techmeme dot com for the link and full context!)

Uber COO Andrew Macdonald said he's not seeing proportional productivity gains from increasing AI costs. bit.ly/4e3w4PC

What is your most encouraging “just wait” advice for young couples/new parents?